Goldman Sachs anticipates
double-digit earnings growth for
Teva Pharmaceutical Industries through 2026.
Piper Sandler has increased its stock price target for Teva due to the
Austedo outlook. Despite Teva's CEO and EVP selling considerable shares, the stocks continue to impress, with an uptrend of 3.4% over the last week. Positive evaluations are driven by the company's branded growth story, valuation upside potential, impressive returns and execution of its 'Pivot to Growth' strategy. However, some voices discourage investment in Teva, citing other stocks as preferred options. Institutions, holding 72%-74% of Teva's stake, continue to back the company, with several boosting their positions, indicating a positive longer-term outlook.
Blackstone backs a $400M venture on Teva's drug for ulcerative colitis and Crohn's. An analyst rating update from Piper Sandler and raised price targets from UBS and Truist Financial signifies a bullish sentiment.
Barclays elevated target to $38 following strong Q4 earnings. The biotech firm shows a return to profitability with a shift towards branded drugs. Recently, Teva stocks hit a 52-week high thrice, and investors' confidence is buoyed by JPMorgan and UBS raising price targets.
Teva Pharmaceutical Stocks News Analytics from Mon, 12 May 2025 07:00:00 GMT to Sat, 07 Mar 2026 20:47:22 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor 5
